Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents

Executive Summary

Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.

Advertisement

Related Content

Product Liability Defense Favored By Industry Appears To Have Supreme Court Support
Gilead False Claims Case: Government Opposes Supreme Court Review But Thinks Suit Should Be Tossed
PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial
PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return
HCV Patent Case: With "Unclean Hands," Merck Can't Collect Jury Award From Gilead
Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel